TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
This Quarter Return
+2.75%
1 Year Return
-56.28%
3 Year Return
-45.76%
5 Year Return
+44.93%
10 Year Return
–
AUM
$132M
AUM Growth
+$132M
(+0.35%)
Cap. Flow
-$4.94M
Cap. Flow
% of AUM
-3.75%
Top 10 Holdings %
Top 10 Hldgs %
61.26%
Holding
46
New
7
Increased
7
Reduced
14
Closed
11
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$6.5M |
| 2 |
Abbott
ABT
|
$4.91M |
| 3 |
McKesson
MCK
|
$4.7M |
| 4 |
Becton Dickinson
BDX
|
$3.96M |
| 5 |
Teva Pharmaceuticals
TEVA
|
$3.39M |
Top Sells
| 1 |
Amgen
AMGN
|
$7.25M |
| 2 |
DocGo
DCGO
|
$4.45M |
| 3 |
Viatris
VTRS
|
$2.5M |
| 4 |
RadNet
RDNT
|
$2.33M |
| 5 |
Ascendis Pharma
ASND
|
$2.14M |
Sector Composition
| 1 | Healthcare | 99.39% |
| 2 | Consumer Staples | 0.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Viatris
VTRS
$12.3B
| $12.5M | 3.86% |
1,250,000
-250,000
| -17% | -$2.5M |
|
|
MDRX
2
DELISTED
Veradigm Inc. Common Stock
MDRX
| $11.7M | 3.62% |
930,000
-20,000
| -2% | -$252K |
|
3
Phreesia
PHR
$1.88B
| $8.99M | 2.78% |
290,000
-30,000
| -9% | -$930K |
|
4
Collegium Pharmaceutical
COLL
$1.22B
| $8.06M | 2.49% |
375,000
+20,000
| +6% | +$430K |
|
5
Tenet Healthcare
THC
$16.3B
| $7.73M | 2.39% |
95,000
-5,000
| -5% | -$407K |
|
6
Tactile Systems Technology
TCMD
$297M
| $7.48M | 2.31% |
300,000
-60,000
| -17% | -$1.5M |
|
|
7
BioMarin Pharmaceuticals
BMRN
$11.2B
| $6.5M | 2.01% |
+75,000
| New | +$6.5M |
|
|
STRM
8
DELISTED
Streamline Health Solutions
STRM
| $6.26M | 1.94% |
4,930,882
| – | – |
|
|
9
McKesson
MCK
$85.4B
| $5.98M | 1.85% |
14,000
+11,000
| +367% | +$4.7M |
|
10
SI-BONE Inc
SIBN
$719M
| $5.4M | 1.67% |
200,000
-75,000
| -27% | -$2.02M |
|
11
Sanofi
SNY
$121B
| $5.12M | 1.58% |
95,000
| – | – |
|
|
12
Abbott
ABT
$231B
| $4.91M | 1.52% |
+45,000
| New | +$4.91M |
|
13
AngioDynamics
ANGO
$417M
| $4.85M | 1.5% |
465,000
-10,000
| -2% | -$104K |
|
|
14
RadNet
RDNT
$5.52B
| $4.57M | 1.41% |
140,000
-71,500
| -34% | -$2.33M |
|
15
Cerus
CERS
$251M
| $4.31M | 1.33% |
1,750,000
-500,000
| -22% | -$1.23M |
|
16
AtriCure
ATRC
$1.84B
| $4.2M | 1.3% |
85,000
+44,624
| +111% | +$2.2M |
|
|
17
Becton Dickinson
BDX
$55.3B
| $3.96M | 1.22% |
+15,000
| New | +$3.96M |
|
|
18
Teva Pharmaceuticals
TEVA
$21.1B
| $3.39M | 1.05% |
+450,000
| New | +$3.39M |
|
19
Alkermes
ALKS
$4.78B
| $3.13M | 0.97% |
100,000
+25,000
| +33% | +$783K |
|
20
InMode
INMD
$944M
| $2.8M | 0.87% |
75,000
-40,000
| -35% | -$1.49M |
|
21
Ironwood Pharmaceuticals
IRWD
$214M
| $2.39M | 0.74% |
225,000
+15,000
| +7% | +$160K |
|
22
DexCom
DXCM
$29.5B
| $2.06M | 0.64% |
+16,000
| New | +$2.06M |
|
23
Rigel Pharmaceuticals
RIGL
$697M
| $1.61M | 0.5% |
1,250,000
-750,000
| -38% | -$968K |
|
|
24
DocGo
DCGO
$153M
| $1.26M | 0.39% |
135,000
-475,000
| -78% | -$4.45M |
|
25
Spectrum Brands
SPB
$1.38B
| $781K | 0.24% |
+10,000
| New | +$781K |
|